-
Drug Trials Snapshots: FILSPARI
06 May 2024 18:44 GMT
… to make decisions regarding medical care. Always speak to … participated in the clinical trials?
FDA granted accelerated approved to … this drug?
A trial comparing FILSPARI to irbesartan (a drug that … available treatment or placebo used in clinical trials that …
-
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
24 Apr 2024 09:44 GMT
… access to this important medicine."
The European … slope endpoint versus irbesartan and demonstrated clinically … , manufacturing and marketing pharmaceutical products for precision healthcare … granted Orphan Drug Designation for the treatment of IgAN …
-
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
24 Apr 2024 11:05 GMT
… slope endpoint versus irbesartan and demonstrated … treatment. Following the 110-week blinded treatment period, treatment with study medication … manufacturing and marketing pharmaceutical products for precision … anticipated future clinical trials will not …
-
Novartis Secures Phase III Fabhalta Win in IgAN as FDA Starts Priority Review
16 Apr 2024 21:45 GMT
… III trial results for its potential multibillion-dollar drug Fabhalta … IgAN after linking the treatment to a 45% proteinuria … decline in the irbesartan control group. The FDA authorized Calliditas’ … is a freelance pharmaceutical and biotech writer based in …
-
Pressure medications may cause diabetes
16 Apr 2024 04:20 GMT
… is that some drugs used in the treatment of high blood … .
In cases where alternative medications can be used, many … the risk of diabetes. Doctors should therefore consider the patient … receptor blockers (ARBs such as irbesartan, candesartan and losartan) have …
-
Renalys Pharma Submits an IND Application for a Phase III Clinical Trial of sparsentan for IgA Nephropathy in Japan
08 Apr 2024 09:23 GMT
… Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical … In 2023, Travere received FDA accelerated approval for sparsentan … compared with active control irbesartan.
Renalys Pharma is committed … unmet need for such treatment in Japan.
About …
-
Renalys Pharma seeks Japanese PMDA nod to begin phase III trial of sparsentan for IgA nephropathy
09 Apr 2024 11:47 GMT
… Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical … In 2023, Travere received FDA accelerated approval for sparsentan … compared with active control irbesartan.
Renalys Pharma is committed … unmet need for such treatment in Japan.
Renalys …
-
Handok hosts symposium, marking launch of hypertension drug Aprovasc
20 Mar 2024 07:22 GMT
… 301 and 302 clinical trials, which served as … the Gangnam-gu Internal Medicine Association, presided over … delivered lectures.
Aprovasc combines irbesartan, an ARB (angiotensin … and better treatment adherence compared to single-drug combination therapy.
…
-
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
11 Mar 2024 11:05 GMT
… S. Food and Drug Administration (FDA) for conversion … treatment. Following the 110-week blinded treatment period, treatment with study medication … chronic slope versus irbesartan, narrowly missing statistical … anticipated future clinical trials will not proceed …
-
20 more medicines for cancer, hypertension, mental illness now VAT-exempt
07 Mar 2024 20:59 GMT
… value-added tax (VAT).
The medicines Pemetrexed, Entrectinib, Asciminib, Palbociclib, and … on Losartan Potassium+Amlodipine and Irbesartan+Amlodipine.
Meanwhile, for those struggling … this year also exempted 21 medicines for cancer, diabetes, high …